NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are...
Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau
- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints;...
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint -- and now have legal rights worth protecting. Levi & Korsinsky...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people...
Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a...
Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.
/Computer%20memory%20closeup%20by%20Nor%20Gal%20via%20Shutterstock.jpg)
The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.27%. September E-mini S&P futures...